PARIS & BOULDER, Colo.--(BUSINESS WIRE)--Regulatory News:

SpineGuard (Paris:ALSGD) (FR0011464452 – ALSGD), an innovative company that deploys its DSG® (Dynamic Surgical Guidance) sensing technology to secure and streamline the placement of bone implants, reminds its shareholders that the Annual Shareholder's Meeting will be held on Wednesday, June 8, 2022 at 10:00 am at the offices of the law firm Ashurst Paris, located at 18 square Edouard VII, 75009 Paris, and details its terms and conditions as well as its letter to shareholders.

Voting procedures

Shareholders will be able to attend the Shareholders' Meeting in person or to vote remotely, before the Shareholders' Meeting via the "Votaccess" e-platform, or by mail or by proxy, in accordance with the procedures indicated in the bulletin des Annonces Légales Obligatoires dated on May 2, 2022 (French).

e-voting using the "Votaccess" e-platform will be available from 09:00 am CEST today May 20. If your broker or bank is a member of the Votaccess e-platform, access is made using the same regular login and password used to access your broker / bank e-services. The Votaccess e-platform will close on Tuesday, June 7 at 03:00 pm CEST.

The possibility of voting or giving a proxy by mail will end on June 3, 2022 (end of the deadline for receiving voting forms).

Documents including the shareholders' brochure ('brochure de convocation' in French only) and the voting form are available at the following links:

• Voting Form
• Shareholders' Brochure (French)

All documents related to this Shareholder's Meeting are available on SpineGuard's website, www.spineguard.com, in the Investors/General Meetings section.

More on Colorado Desk

• New Release: 'The Invisible Alternative' Unveiled by Atrisk Corporation, Resilient
• Colorado: Governor Polis Appoints Eang M. Man to the Boulder County Court
• Governor Polis Appoints Coloradans to Colorado Parks and Wildlife Commission
• Colorado: Hickenlooper, Polis, DeGette, Neguse, Crow, Pettersen Denounce Republicans' Reckless Budget Bill, Pressure House Members to Vote Against It
• Cynthia Pinot Among Artists Selected for Renowned London Art Biennale 2025

For any questions regarding voting procedures, shareholders may contact the Investor Relations team by e-mail at the following address: spineguard@newcap.eu

Should the required quorum not be met, a second Meeting would be called for June 30, 2022 at 10:00am CEST, at the offices of the law firm Ashurst Paris, located at 18 square Edouard VII, 75009 Paris

Shareholders are reminded that the AMF strongly encourages them to exercise their voting rights, which is a fundamental prerogative of the shareholder.

Letter to shareholders

SpineGuard presents its letter to shareholders

"The growing interest triggered by our latest advances offers real value creation perspectives. It is stimulating the entire SpineGuard team who strives to reveal the full potential of the DSG technology, unique in its capacity to secure and streamline the placement of implants in bone while minimizing the recourse to X-rays," said SpineGuard's Co-founders, Pierre Jérôme, CEO, and Stéphane Bette, Deputy CEO.

Read the full letter to shareholders HERE

About SpineGuard®

Founded in 2009 in France and the USA by Pierre Jérôme and Stéphane Bette, SpineGuard is an innovative company deploying its proprietary radiation-free real time sensing technology DSG® (Dynamic Surgical Guidance) to secure and streamline the placement of implants in the skeleton. SpineGuard designs, develops and markets medical devices that have been used in over 80,000 surgical procedures worldwide. Seventeen studies published in peer-reviewed scientific journals have demonstrated the multiple benefits DSG® offers to patients, surgeons, surgical staff and hospitals. Building on these solid fundamentals and several strategic partnerships, SpineGuard has expanded its technology platform in a disruptive innovation: the « smart » pedicle screw launched late 2017 and is broadening the scope of applications in dental implantology and surgical robotics. DSG® was co-invented by Maurice Bourlion, Ph.D., Ciaran Bolger, M.D., Ph.D., and Alain Vanquaethem, Biomedical Engineer.

More on Colorado Desk

• Real Estate Experts Highlight Jersey Shore as a Smart Buy in 2025
• Colorado: Governor Polis: Congressional Republicans Causing Devastating, Negative Impact From Passing One Big Budget-Busting Bureaucracy-Building Act
• Colorado: Governor Polis Celebrates 4th of July, Marking 249 Years of Independence From Monarchy and Tyranny
• $18 Price Target Issued in New Research Report After $34 Million Revenue Forecast from Acquisition; $101.5 Million Net Revenue in 2025; NAS DAQ: IQST
• West Dentistry Welcomes New Oral Surgeon to Enhance Patient Care

For further information, visit www.spineguard.com

Disclaimer

The SpineGuard securities may not be offered or sold in the United States as they have not been and will not be registered under the Securities Act or any United States state securities laws, and SpineGuard does not intend to make a public offer of its securities in the United States. This is an announcement and not a prospectus, and the information contained herein does and shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in the United States in which such offer, solicitation or sale would be unlawful prior to registration or exemption from registration.

Contacts

SpineGuard
Pierre Jérôme
CEO & Chairman
Tel: +33 1 45 18 45 19
p.jerome@spineguard.com

SpineGuard
Manuel Lanfossi
CFO
Tel: +33 1 45 18 45 19
m.lanfossi@spineguard.com

NewCap
Investor Relations & Financial Communication
Mathilde Bohin / Pierre Laurent
Tel.: +33 1 44 71 94 94
spineguard@newcap.eu

---

Show All News | Report Violation